Slide 1: Annual General Meeting
For personal use only Annual General Meeting ASX:IPD November 2016 1
Slide 2: Disclaimer
For personal use only • The material contained in this document is a presentation of general information about the activities of ImpediMed Limited (“ImpediMed”) current as at the date of this presentation. The information is provided in a summary form, does not purport to be complete and should not
Slide 3: Forward Looking Statements
For personal use only Forward • Certain statements in this presentation may constitute forward-looking statements or statements about future matters that are based on management’s current expectations Looking and beliefs. The forward-looking statements in this release include statements regarding th
Slide 4: Investment Summary
For personal use only Investment Summary Proven, Proprietary Technology, IPD’s Bioimpedance Spectroscopy (BIS) - provides a simple, accurate, non-invasive system for precisely measuring and monitoring tissue composition and fluid status in a variety of disease states; scientific/clinical validation
Slide 5: Major Achievements Last 12 Months
For personal use only CY 2016 Oct • 55 Leading Cancer Centres now using L-Dex on high risk breast Major cancer patients • AU$2.8 million Research & Development tax credit received Achievements • Mayo Clinic to use SOZO™ in CHF study Last 12 Sep • Study published on efficacy of L-Dex in clinical prac
Slide 6: Corporate Overview
For personal use only Corporate Overview SHARE PRICE PERFORMANCE ASX listed (October 2007) Management Change July 2012 S&P/ASX 300 – added March 2015 Operations in US (San Diego, CA and Bloomington, MN), Australia (Brisbane) and Europe (Greece) (77 staff) Market capitalisation ~AU$520M (~374M shares
Slide 7: Financial Year 2016
For personal use only Financial Year 2016 ONCOLOGY REVENUE (000’s) CASH BALANCE (000’s) MARKET CAP (millions) $3,500 $90,000 $400 $2,625 $67,500 $300 $1,750 $45,000 $200 $875 $22,500 $100 $‐ $‐ $0 FY12 FY13 FY14 FY15 FY16 FY12 FY13 FY14 FY15 FY16 FY12 FY13 FY14 FY15 FY16 7
Slide 8: Bioimpedance Spectroscopy (BIS) Technology
For personal use only Bioimpedance Spectroscopy (BIS) Technology BIS Technology Advantages • Simple and sophisticated method for measuring fluid and tissue composition Low Frequency • A rapid, non-invasive system that provides highly Fluid accurate data • The full frequency spectrum approach used by
Slide 9: What's New: SOZO
What’s New For personal use only • No longer requires gel backed electrodes • Patients no longer required to be prone when being tested Simple and • Testing no longer requires an examination room • Cloud based, HIPPA security compliant Sophisticated • Designed for improved workflow in clinics reduci
Slide 10: Patient Centred Design
For personal use only Data Means Nothing without a Patient at the Centre Patient Patient Centred Design Designed with over 15 years of patient and Centred clinician based feedback to move SOZO™ from research based to inside and outside the clinic Design use. Simple User Interface With only seconds f
Slide 11: For Lymphoedema in Cancer Survivors
For personal use only For Lymphoedema in Cancer Survivors 11
Slide 12: L-Dex for the Early Detection of Lymphoedema
For personal use only with L-Dex for the Early Detection of Lymphoedema Lymphoedema is a leading post-surgical complication for many breast cancer patients and greatly impacts quality of life Simple and accurate measurement of fluid in limbs allows early detection and intervention Cancer treatment c
Slide 13: Commercialisation of L-Dex Well on Track
For personal use only Commercialisation 2015 - US Commercial launch of L-Dex commenced December 2015 of L-Dex 2016 - National Launch Well on Track • 55 (anticipate 65+ by end of CY) multi-disciplinary cancer centres utilising L-Dex in their high risk breast cancer programs • Integrating L-Dex into c
Slide 14: For CHF
14 For personal use only For CHF
Slide 15: Heart Failure: Large and Compelling Opportunity
For personal use only Heart Failure Large and Compelling Opportunity Heart Failure CHF is Among the Most Expensive Diseases for Medicare Is a chronic, progressive condition in which the heart • Estimated 5.7 million people in the US suffer from heart failure muscle is unable to pump enough blood thr
Slide 16: CMS is Aggressively Addressing Escalating Costs
For personal use only CMS is Aggressively Addressing Escalating Costs Chronic Care Quality Measures Hospital Readmission Reduction Plan (HRRP) Key CMS chronic care quality measurement programs includes Physician Quality Reporting System (PQRS): HRRP penalises hospitals with relatively higher readmis
Slide 17: Current Heart Failure Monitoring Methods
For personal use only Current Heart Failure Monitoring Methods Inaccurate or Invasive and Expensive The assessment of fluid burden is critical to the Current monitoring methods have major management of CHF patients shortcomings • Current practice is to monitor CHF patients daily for • Weight Scale -
Slide 18: Optimising Outcomes for Heart Failure Patients
For personal use only Optimising Outcomes for Heart Failure Patients HF Classification % of Patient Population (est) Class I 35% Class II 35% Class III 25% Class IV 5% Heart HeartFailure Hospitalisation • Class III/IV HF patients account for the majority of the Failure Hospitalisation annual HF read
Slide 19: Heart Failure Program Making Rapid Progress
For personal use only Heart Failure Program Making Rapid Progress In Progress Targeted Achieved Regulatory CHF Advisory Boards • FDA 510(k) Submission Early CY2017 • US Key Opinion Leaders • CE Mark anticipated Early CY2017 • Harvard Clinical Research Institution • US Reimbursement Clinical Research
Slide 20: Noted Medical Advisory Board Providing Guidance
For personal use only Noted Medical Advisory US Advisory Board Members and Clinical Research Team Board Paul Friedman, MD - Vice Chair, Department of Cardiovascular Medicine, Medical Providing Director, Remote Monitoring, Mayo Clinic Guidance Roy Small, MD - FACC, FSCAI, Medical Director of Clinical
Slide 21: Potential CHF Business Model
For personal use only Potential CHF Business Model • Initial focus on Class III CHF patients CHF - Estimated at 25% of US 5.7 million CHF patients - Goal is to monitor and manage the disease progression for Class III patients • Initial phase to establish SOZOTM CHF program in select key clinics - Ba
Slide 22: Important Next Milestones
For personal use only Important Next 18 Months Milestones Regular updates on L-Dex adoption and sales expansion • CE Mark for SOZO™ • Geographical expansion • FDA clearance for SOZO™ • Conversion and integration of SOZO™ into clinical practices (short-term resource focus) • Global studies drive adop
Slide 23: Innovation is at our core
For personal use only “Innovation is at our core and will be the life-blood of our future” 23
Slide 24: Appendix
24 For personal use only Appendix
Slide 25: Management Team Has Deep and Broad Commercialisation Experience
Management Team Has Deep For personal use only and Broad Commercialisation Experience Jack Cosentino David Adams Ann Holder Catherine Kingsford Dennis Schlaht Frank Vicini, MD Morten Vigeland Chief Strategy Officer SVP Ventures, SVP General SVP Medical Affairs SVP Quality, R&D Chief Medical Officer
Slide 26: Board of Directors
Board of Directors For personal use only Elizabeth Gaines Gary Goetzke Non-Executive Director Juris Doctorate Non-Executive Director • On Board since March 2016 • Non-Executive Director of • On Board since August Fortescue Metals Group 2016 Ltd, NextDC Ltd and Nine • 15+ years in senior Entertainmen